BRAF
BRAF (B-Raf proto-oncogene, serine/threonine kinase; also BRAF1 or BRAF-1) is a RAF family protein kinase that relays mitogenic signals from the cell membrane to the nucleus. It phosphorylates MAP2K1 and so activates the MAP kinase signalling pathway. Browse Assay Genie's current range of BRAF research reagents below, or read on for the biology behind the target.
BRAF is a protein kinase involved in transducing mitogenic signals from the cell membrane to the nucleus. It phosphorylates MAP2K1, which activates the MAP kinase signal transduction pathway, and it also phosphorylates PFKFB2. Through the MAP kinase/ERK pathway, BRAF influences cell division, differentiation and secretion. UniProt also notes that it may play a role in the postsynaptic responses of hippocampal neurons.
The BRAF gene encodes a serine/threonine-protein kinase that belongs to the protein kinase superfamily, the TKL Ser/Thr protein kinase family and the RAF subfamily. HGNC places it in the RAF family within the mitogen-activated protein kinase kinase kinases. The protein is reported in the nucleus, the cytoplasm and at the cell membrane. The mouse ortholog is Braf, and a pseudogene of the human gene has been identified on the X chromosome. Researchers working with the BRAF protein often study it alongside its substrates in the MAP kinase cascade.
The gene was originally named v-raf murine sarcoma viral oncogene homolog B, which is reflected in its proto-oncogene designation. Mutations in the BRAF gene, most commonly V600E, are the most frequently identified cancer-causing mutations in melanoma. They have also been found in non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukaemia and lung adenocarcinoma. Mutations are also associated with cardiofaciocutaneous, Noonan and Costello syndromes, which have overlapping phenotypes. This makes BRAF an important subject in both cancer biology and developmental disorder research.
Mutations in BRAF, most commonly V600E, are the most frequently identified cancer-causing mutations in melanoma and occur in many other cancers.
BRAF phosphorylates MAP2K1 and activates the MAP kinase pathway, which affects cell division, differentiation and secretion.
Mutations in BRAF are associated with cardiofaciocutaneous, Noonan and Costello syndromes, which show overlapping phenotypes.
BRAF may play a role in the postsynaptic responses of hippocampal neurons, an area of interest in neurobiology.
BRAF is a serine/threonine protein kinase that transduces mitogenic signals from the cell membrane to the nucleus. It phosphorylates MAP2K1, activating the MAP kinase pathway, and also phosphorylates PFKFB2. The pathway it regulates affects cell division, differentiation and secretion.
BRAF is also written BRAF1 or BRAF-1. HGNC gives the full name as B-Raf proto-oncogene, serine/threonine kinase, and the previous name was v-raf murine sarcoma viral oncogene homolog B. UniProt lists it as serine/threonine-protein kinase B-raf.
Yes. BRAF mutations, most commonly V600E, are frequent in melanoma and occur in colorectal, thyroid and lung cancers, among others. They are also linked to cardiofaciocutaneous, Noonan and Costello syndromes. The mouse ortholog is Braf; check the datasheet of any product for its validated reactivity.
Other RAF family kinases, MAP kinase pathway components and BRAF substrates with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P15056; product specifications from Assay Genie datasheets.